Junping Shi

493 total citations
24 papers, 339 citations indexed

About

Junping Shi is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Junping Shi has authored 24 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Cancer Research and 9 papers in Surgery. Recurrent topics in Junping Shi's work include Cancer Genomics and Diagnostics (9 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Junping Shi is often cited by papers focused on Cancer Genomics and Diagnostics (9 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Junping Shi collaborates with scholars based in China and United States. Junping Shi's co-authors include Haitao Zhao, Xiaobo Yang, Honglin Guo, Xiaoliang Shi, Kai Wang, Wenting Chen, Jianzhen Lin, Xinting Sang, Junfeng Liu and Ke Hu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Junping Shi

24 papers receiving 337 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Junping Shi China 11 184 144 134 109 86 24 339
Tessa J.J. de Bitter Netherlands 11 150 0.8× 134 0.9× 121 0.9× 84 0.8× 56 0.7× 23 286
Dezuo Dong China 9 122 0.7× 59 0.4× 77 0.6× 119 1.1× 56 0.7× 20 283
Yasuyuki Kawamoto Japan 13 399 2.2× 222 1.5× 210 1.6× 81 0.7× 128 1.5× 68 530
Shumei Jiang China 12 162 0.9× 111 0.8× 64 0.5× 95 0.9× 92 1.1× 29 333
Helen Bolanaki Greece 8 114 0.6× 78 0.5× 77 0.6× 138 1.3× 120 1.4× 20 301
Xiao-Dong Zhu China 10 130 0.7× 59 0.4× 83 0.6× 155 1.4× 128 1.5× 14 375
Renfeng Shan China 12 76 0.4× 68 0.5× 56 0.4× 122 1.1× 116 1.3× 27 297
Ning‐Fu Peng China 12 150 0.8× 65 0.5× 71 0.5× 61 0.6× 131 1.5× 20 356
L. Cannella Italy 9 143 0.8× 77 0.5× 69 0.5× 70 0.6× 46 0.5× 26 276
Hajime Shibuya Japan 8 197 1.1× 88 0.6× 86 0.6× 196 1.8× 217 2.5× 20 444

Countries citing papers authored by Junping Shi

Since Specialization
Citations

This map shows the geographic impact of Junping Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junping Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junping Shi more than expected).

Fields of papers citing papers by Junping Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junping Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junping Shi. The network helps show where Junping Shi may publish in the future.

Co-authorship network of co-authors of Junping Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Junping Shi. A scholar is included among the top collaborators of Junping Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junping Shi. Junping Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Zhenhai, et al.. (2022). DEPDC1B promotes development of cholangiocarcinoma through enhancing the stability of CDK1 and regulating malignant phenotypes. Frontiers in Oncology. 12. 842205–842205. 1 indexed citations
2.
Wang, Shuo, Tao Liu, Xuan Qiu, et al.. (2021). Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients. HepatoBiliary Surgery and Nutrition. 10(2). 172–179. 27 indexed citations
3.
Li, Wenxin, Zhiqiang Hao, Hai Shang, et al.. (2021). Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report. Annals of Translational Medicine. 9(18). 1487–1487. 8 indexed citations
4.
Lu, Shanshan, Junping Shi, Xiaobo Zhang, et al.. (2021). Comprehensive genomic profiling and prognostic analysis of cervical gastric-type mucinous adenocarcinoma. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 479(5). 893–903. 22 indexed citations
5.
Zheng, Yuanwen, Yejun Qin, Wei Gong, et al.. (2021). Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma. Journal of Gastrointestinal Oncology. 12(6). 2631–2642. 20 indexed citations
6.
Wang, Yu, et al.. (2020). Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report. The Oncologist. 26(3). 178–181. 14 indexed citations
7.
Zhang, Nan, Junping Shi, Xiaoliang Shi, Wenting Chen, & Junfeng Liu. (2020). <p>Mutational Characterization and Potential Prognostic Biomarkers of Chinese Patients with Esophageal Squamous Cell Carcinoma</p>. OncoTargets and Therapy. Volume 13. 12797–12809. 28 indexed citations
8.
Li, Jinghua, et al.. (2020). Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation. The Oncologist. 25(10). 826–832. 3 indexed citations
9.
Zhang, Wei, Junping Shi, Yingying Wang, et al.. (2020). Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers. Cancer Immunology Immunotherapy. 70(4). 1001–1014. 36 indexed citations
10.
Li, Wenliang, Zhu Zhu, Wei Huang, et al.. (2020). Alterations of DNA damage repair genes in Chinese colorectal cancer patients.. Journal of Clinical Oncology. 38(15_suppl). e16121–e16121. 1 indexed citations
11.
Hu, Jinwei, Kai You, Lijuan Chen, et al.. (2020). Abstract 3548: Loss of heterozygosity (LOH) as a candidate biomarker of PARP inhibitor sensitivity in Chinese solid tumor patients. Cancer Research. 80(16_Supplement). 3548–3548. 1 indexed citations
12.
Xu, Shifeng, Wei Rao, Yuanwen Zheng, et al.. (2020). The landscape of MET mutations in Chinese biliary tract cancers.. Journal of Clinical Oncology. 38(15_suppl). e16652–e16652. 1 indexed citations
13.
Lin, Jianzhen, Xu Yang, Yinghao Cao, et al.. (2020). Genomics and translational precision oncology for 803 patients with biliary tract cancer.. Journal of Clinical Oncology. 38(15_suppl). 4589–4589. 4 indexed citations
14.
Wang, Guanghui, Fenglong Bie, Guangxu Li, et al.. (2020). Study of the co-expression gene modules of non-small cell lung cancer metastases. Cancer Biomarkers. 30(3). 321–329. 3 indexed citations
15.
Zhang, Wei, Junping Shi, Zhiqiang Han, et al.. (2020). Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation. The Oncologist. 25(5). 375–379. 17 indexed citations
16.
Lin, Jianzhen, Junping Shi, Honglin Guo, et al.. (2019). Alterations in DNA Damage Repair Genes in Primary Liver Cancer. Clinical Cancer Research. 25(15). 4701–4711. 80 indexed citations
17.
Guan, Yan, Yan Li, Honglin Guo, et al.. (2019). Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion. The Oncologist. 24(8). 1027–1030. 11 indexed citations
18.
Lin, Jianzhen, Yi Bai, Songhui Zhao, et al.. (2019). Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice. Annals of Translational Medicine. 7(18). 467–467. 15 indexed citations
19.
Wen, Lu, Xiuxiu Li, Junping Shi, et al.. (2019). Allele-specific expression mediates primary resistance to poly (ADP-ribose) polymerase inhibitor therapy in a case of BRCA1/2 double-germline mutant gastric cancer. Journal of International Medical Research. 48(3). 1219685778–1219685778. 3 indexed citations
20.
Song, Chun‐Qing, Junping Shi, Ming Yao, et al.. (2018). Next-Generation Sequencing Assisted in Establishing the Diagnosis and Treatment for a Chinese Patient With Breast and Lung Multiple Primary Malignancies. Journal of Thoracic Oncology. 13(7). e109–e111. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tessa J.J. de Bitter Breakdown of academic impact, for papers by Dezuo Dong Breakdown of academic impact, for papers by Yasuyuki Kawamoto Breakdown of academic impact, for papers by Shumei Jiang Breakdown of academic impact, for papers by Helen Bolanaki Breakdown of academic impact, for papers by Xiao-Dong Zhu Breakdown of academic impact, for papers by Renfeng Shan Breakdown of academic impact, for papers by Ning‐Fu Peng Breakdown of academic impact, for papers by L. Cannella Breakdown of academic impact, for papers by Hajime Shibuya
Rankless by CCL
2026